Evidence map›Paper›PMID 28936783›Full record

ArticleClinical oral investigations2018

Experimental variation of the level and the ratio of angiogenic and osteogenic signaling affects the spatiotemporal expression of bone-specific markers and organization of bone formation in ectopic sites.

Norman Moser, Jan Goldstein, Phillip Kauffmann, Matthias Epple, Henning Schliephake

Abstract read
PubMed Publisher
In one paragraph

Article in Clinical oral investigations, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.3field-weighted citation impact, top 44% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Norman MoserDepartment of Oral and Maxillofacial Surgery, George Augusta University, Robert-Koch-Str. 40, 37075, Göttingen, Germany.
Jan GoldsteinDepartment of Oral and Maxillofacial Surgery, George Augusta University, Robert-Koch-Str. 40, 37075, Göttingen, Germany.
Phillip KauffmannDepartment of Oral and Maxillofacial Surgery, George Augusta University, Robert-Koch-Str. 40, 37075, Göttingen, Germany.
Matthias EppleInorganic Chemistry and Center for Nanointegration Duisburg-Essen (CeNIDE), University of Duisburg-Essen, Universitaetsstr. 5-7, 45117, Essen, Germany.
Henning SchliephakeDepartment of Oral and Maxillofacial Surgery, George Augusta University, Robert-Koch-Str. 40, 37075, Göttingen, Germany. Schliephake.henning@med.uni-goettingen.de.ORCID http://orcid.org/0000-0002-2008-7188
University of Göttingen · DEUniversity of Duisburg-Essen · DE

Funding

Federal Ministry of Education and Research (BMBF) 13N10003
6 · The paper itself

Abstract

objectivesThe aim of the present study was to test the hypothesis that the ratio of angiogenic and osteogenic signaling affects ectopic bone formation when delivered in different amounts. MATERIALS AND

methodsPorous composite PDLLA/CaCO

resultsThe evaluation showed that the combined delivery of bone morphogenetic protein BMP2 and VEGF in different dosage combinations did not enhance the overall quantity of ectopic bone formation compared to the delivery of BMP2 alone. The addition of VEGF generally upregulated Runx2 after 4 weeks, which may have retarded terminal osteogenic differentiation. However, slow combined delivery of 1.5-2.0 μg BMP2 combined with 50 ng VEGF165 over a period of 5 weeks supported a more even distribution of bone formation across the implanted scaffolds whereas higher amounts of VEGF did not elicit this effect.

conclusionsThe findings suggest that structural organization rather than the quantity of ectopic bone formation is affected by the dosage and the ratio of BMP2 and VEGF levels at the observed intervals. CLINICAL RELEVANCE: The development of carriers for dual growth factor delivery has to take into account the necessity to carefully balance the ratio of growth release.

Indexed as

ButtocksAlkaline PhosphataseAnimalsBone Morphogenetic Protein 2Core Binding Factor Alpha 1 SubunitMaleOsteogenesisPorosityRatsRats, WistarRecombinant ProteinsTissue ScaffoldsTransforming Growth Factor betaVascular Endothelial Growth Factor AAlkaline PhosphataseBone Morphogenetic Protein 2Core Binding Factor Alpha 1 Subunitrecombinant human bone morphogenetic protein-2Recombinant ProteinsRunx2 protein, ratTransforming Growth Factor betaVascular Endothelial Growth Factor AAlkaline phosphataseBone morphogenetic proteinOsteogenesisRunx2Vascular endothelial growth factor

Identifiers

PMID28936783
OpenAlexW2759058496

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.